Xilio Therapeutics (NASDAQ:XLO) Announces Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Xilio Therapeutics (NASDAQ:XLO) posted its quarterly earnings results on Tuesday. The company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.08, FiscalAI reports. The firm had revenue of $12.65 million for the quarter, compared to the consensus estimate of $8.52 million. Xilio Therapeutics had a negative net margin of 80.05% and a negative return on equity of 393.01%.

Xilio Therapeutics Stock Performance

XLO traded down $0.09 during midday trading on Tuesday, hitting $7.64. The company had a trading volume of 2,922 shares, compared to its average volume of 36,189. Xilio Therapeutics has a twelve month low of $6.47 and a twelve month high of $16.52. The company has a market capitalization of $45.66 million, a PE ratio of -1.43 and a beta of -0.16. The firm’s 50-day simple moving average is $8.05 and its 200-day simple moving average is $9.01.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of XLO. Squarepoint Ops LLC raised its position in shares of Xilio Therapeutics by 39.6% during the third quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after acquiring an additional 93,338 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Xilio Therapeutics by 68.3% in the fourth quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after acquiring an additional 139,716 shares during the last quarter. Jane Street Group LLC acquired a new stake in Xilio Therapeutics in the fourth quarter worth about $27,000. State Street Corp increased its position in Xilio Therapeutics by 13.7% in the fourth quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after purchasing an additional 22,500 shares during the period. Finally, Velan Capital Investment Management LP bought a new stake in Xilio Therapeutics during the 4th quarter worth about $109,000. 54.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on XLO. Weiss Ratings upgraded shares of Xilio Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Wall Street Zen raised Xilio Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, March 28th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Xilio Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $28.00.

About Xilio Therapeutics

Xilio Therapeutics is a clinical?stage biotechnology company focused on the discovery and development of tumor?targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro?drug versions of potent immune?modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin?12 (IL?12) and interleukin?2 (IL?2) molecules fused to tumor?binding antibodies or peptide ligands.